| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals, Inc. (MDGL) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 15 sells. MDGL is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 452.2K | $241.87M | - | |
| Dir | 205.0K | $109.65M | - | |
| Dir | 200.0K | $106.99M | - | |
| CEO | 150.1K | $80.27M | - | |
| Dir | 29.7K | $15.88M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2025 | Waltermire Robert E.48 | Senior VP, Chief Pharma Dev. | Sell | 442 | $273.41 | $120,847.22 | -8.0% | +2.7% | +70.8% | |
| Jan 17, 2025 | Taub Rebecca | Pres., R&D, And CMO | Sell | 1,689 | $273.41 | $461,789.49 | -0.4% | +2.7% | +70.8% | |
| Dec 3, 2024 | Craves Fred B | Director | Sell | 3,600 | $315.31 | $1,135,121.70 | -13.8% | -2.5% | +80.4% | |
| Nov 25, 2024 | Craves Fred B | Director | Sell | 3,400 | $350.30 | $1,191,028.02 | -10.1% | -6.7% | +71.5% | |
| Nov 21, 2024 | Huntsman Carole | Chief Commercial Officer | Sell | 688 | $316.92 | $218,040.96 | -6.0% | +4.4% | +66.4% | |
| Nov 7, 2024 | Levy Richard S | Director | Sale+OE | 5,000 | $350.00 | $1,750,000.00 | -31.2% | -4.2% | +37.9% | |
| Nov 1, 2024 | Levy Richard S | Director | Sale+OE | 5,000 | $300.94 | $1,504,703.41 | -9.5% | +5.9% | +31.1% | |
| Sep 9, 2024 | Sibold William John | President And CEO | Sell | 6,363 | $243.83 | $1,551,490.29 | -10.2% | +33.4% | +88.0% | |
| Jun 14, 2024 | Waltermire Robert E.48 | Senior VP, Chief Pharma Dev. | Sale+OE | 1,900 | $280.00 | $532,000.00 | -25.7% | -15.4% | +6.5% | |
| Jun 12, 2024 | Waltermire Robert E.48 | Senior VP, Chief Pharma Dev. | Sale+OE | 2,000 | $285.00 | $570,000.00 | -26.7% | -17.5% | +4.0% |